Mito Blend

About Mito Blend (5-Amino-1MQ + MOTS-c + NAD+)

Mito Blend combines three mitochondria-focused research compounds in a single vial: 5-Amino-1MQ (10 mg), a small-molecule NNMT inhibitor studied for reversing diet-induced obesity and boosting cellular NAD+ levels; MOTS-c (10 mg), a mitochondrial-derived peptide researched for metabolic homeostasis, insulin sensitivity, and exercise capacity; and NAD+ (100 mg), the essential coenzyme central to cellular energy production, DNA repair, and healthy aging. Together the blend is researched for metabolic health, fat loss, energy, and mitochondrial function.

Dosing & Reconstitution Guide

— 5-Amino-1MQ 10 mg + MOTS-c 10 mg + NAD+ 100 mg Blend Vial —

Reconstitute: Add 3.0 mL (300 units) bacteriostatic water.
Administration: Subcutaneous injection. Recommended syringe: 1 mL, 29–30 gauge, 5/16″–½″ needle.
Timing: Take in the morning. A fasted state is not required, but is preferred if using the blend for its metabolic benefits.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: 2–3 injections per week.
Cycle Length: 8–12 week cycle, followed by a 2–6 week washout period.
Goal: Metabolic health, fat loss, energy, and mitochondrial support based on preclinical evidence.

Standard Protocol

Phase	Dose	Syringe (U-100)
Full cycle (weeks 1–12)	~1.67 mg 5-Amino-1MQ + ~1.67 mg MOTS-c + ~16.7 mg NAD+ per injection	50 units (0.50 mL), 2–3 days per week

Note: Morning administration is recommended; NAD+ taken late in the day can disrupt sleep in some individuals.

Benefits

• Supports fat loss — 5-Amino-1MQ inhibits NNMT, an enzyme upregulated in fat tissue, shrinking adipocytes in preclinical models.
• Improves metabolic homeostasis and insulin sensitivity (MOTS-c).
• Boosts cellular NAD+ levels for energy production and DNA repair.
• Studied for enhanced exercise capacity and physical performance (MOTS-c).
• Supports mitochondrial biogenesis and function.
• Researched for healthy-aging and cellular-senescence pathways.
• May improve overall energy, focus, and recovery.

Side Effects

While side effects are not common, you may experience:

• Flushing, warmth, or tightness (primarily from the NAD+ component, usually transient)
• Nausea
• Headaches
• Fatigue or lightheadedness
• Irritation or redness at the injection site
• Sleep disruption if taken late in the day

Contraindications

• Do not use when pregnant or nursing.
• Do not use with active cancer — metabolic and NAD+ pathways can influence cell proliferation.
• Use caution with diabetes or hypoglycemia — MOTS-c affects glucose metabolism; monitor blood sugar.
• Use caution with severe kidney or liver disease.
• Consult a physician if taking metabolic or glucose-lowering medications.

Stacking Suggestions

Mito Blend is itself a stack of 5-Amino-1MQ, MOTS-c, and NAD+. Common research pairings to extend it include:

• L-Carnitine – Shuttles fatty acids into mitochondria for oxidation, complementing the blend’s metabolic focus
• AOD-9604 – For additional fat-metabolism research
• Tesamorelin or CJC No DAC + Ipamorelin – GH-axis support for body composition
• SS-31 (Elamipretide) – Mitochondria-targeted peptide for deeper mitochondrial protocols

Research Sources

PubMed-linked citations for verification. Many studies are animal/in-vitro.

1. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PMID: 25738459
2. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109
3. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) reverse high-fat-diet-induced obesity in mice (5-Amino-1MQ research program). Biochem Pharmacol. 2018;147:141-152.
4. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689
5. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-13. PMID: 26785480